Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's leadership, including CEO David-Alexandre C. Gros, M.D., and Chief Scientific Officer and President Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).

Interested parties can register in advance for the presentation webcast through a provided link. Following the live session, a replay of the webcast will be made available on the Company's website in the Events section.

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Company’s website under Events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When is Eledon Pharmaceuticals (ELDN) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Eledon Pharmaceuticals will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT).

Who will represent ELDN at the Guggenheim Biotech Conference 2025?

CEO David-Alexandre C. Gros, M.D., and Chief Scientific Officer and President Steve Perrin, Ph.D., will represent Eledon Pharmaceuticals at the conference.

How can investors access ELDN's Guggenheim Conference presentation?

Investors can register in advance for the webcast through a provided link, and a replay will be available on Eledon's website under the Events section after the live session.

What type of presentation will ELDN deliver at the Guggenheim SMID Cap Conference?

Eledon Pharmaceuticals will participate in a fireside chat format presentation at the conference.